| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 01/18/2005 | US6844003 Compounds derived from benzoic acid esters, composition containing said compounds and use thereof |
| 01/18/2005 | US6843989 Administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand |
| 01/18/2005 | US6843980 Methods for using annexin for detecting cell death in vivo and treating associated conditions |
| 01/18/2005 | CA2064993C Non-porous collagen sheet for therapeutic use, and the method and apparatus for preparing it |
| 01/13/2005 | WO2005002614A1 Methods and compositions for treating disorders of the extracellular matrix |
| 01/13/2005 | WO2005002608A1 Herbal composition |
| 01/13/2005 | WO2005002591A1 Treatment psoriasis, impetigo, tinea by lipositol, cephalin and lecithin |
| 01/13/2005 | WO2005002581A1 Use of osmolytes obtained from extremophilic bacteria for producing medicaments for the external treatment of neurodermatitis |
| 01/13/2005 | WO2005002572A2 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
| 01/13/2005 | WO2005002561A1 Antifungal agent composition for external use |
| 01/13/2005 | WO2005002537A2 Barrier formulation comprising a silicone based emulsion |
| 01/13/2005 | WO2004096248A3 Composition and use of pure iodine dissolved in essential oil of melaleuca alternifolia and/or melaleuca quinquenervia |
| 01/13/2005 | WO2003089569A3 Use of il-19, il-22 and il-24 to treat hematopoietic disorders |
| 01/13/2005 | WO2003080014A8 Two-phase cosmetic or dermatological preparations |
| 01/13/2005 | WO2003074073A3 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof |
| 01/13/2005 | US20050010052 P2X7 receptor (a ligand-gated ion channel) antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases; osteoarthritis |
| 01/13/2005 | US20050010047 Angiogenesis inhibitors; psoriasis; rheumatic disorders; chronic obstructive pulmonary disease |
| 01/13/2005 | US20050010042 Expression vector comprising nucleotide sequences comprising pro-polypeptide for use in the diagnosis, prevention and treatment of cell proliferative, inflammatory, cardiovascuar and nervous system disorders |
| 01/13/2005 | US20050009917 Prostaglandin, e.g., 1R,2R,3R,5R)-5-halo-2-[(1E,3S)-3-cycloalkyl-3-hydroxy-1-propenyl]-3-hydroxycyclopentyl]-(5Z)-5-alkenoic acids; treating in particular, symptoms of atopic dermatitis |
| 01/13/2005 | US20050009902 Treating any types of pruritus such as ocular pruritus, skin pruritus and systemic pruritus with a cannabinoid agonist such as palmidrol and anandamide or a derivative |
| 01/13/2005 | US20050009894 Benzimidazole derivatives and their use as KDR kinase protein inhibitors |
| 01/13/2005 | US20050009874 Tetrahydropyridin or piperidino heterocyclic derivatives |
| 01/13/2005 | US20050009872 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
| 01/13/2005 | US20050009867 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 01/13/2005 | US20050009861 Inverse agonist has a functional efficacy at the alpha 1 and/or alpha 5 receptor subtypes of less than -5%, and the efficacy measured at the alpha 2 and alpha 3 receptor subtypes is greater than 5%, and is preferably a 4-oxo-1,4-tetrahydro-1,5- naphthyridine-3-carboxamide derivative |
| 01/13/2005 | US20050009846 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders |
| 01/13/2005 | US20050009845 Thienopyrimidine compounds as protein tyrosine kinase inhibitors |
| 01/13/2005 | US20050009838 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| 01/13/2005 | US20050009826 5,6,13-trizaza- or 6,13-diazachryseno[2,3-d]-[1,3]dioxole derivatives; enzyme inhibitors; anticarcinogenic, antiproliferative agents; bactericides, fungicides |
| 01/13/2005 | US20050009824 Solubilized topoisomerase poisons |
| 01/13/2005 | US20050009812 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists |
| 01/13/2005 | US20050009808 Azabicyclo compound matrix metalloprotease inibitor and skin preparation |
| 01/13/2005 | US20050009797 Androstane derivative having substituent in 7- abd 17--positions |
| 01/13/2005 | US20050009792 (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses |
| 01/13/2005 | US20050009752 Novel peptides and medicinal uses thereof |
| 01/13/2005 | US20050009144 Transgenic cell comprising nucleotide sequences coding endostatins for use as tool in identifying modulators for treatment and prevention of cell proliferative and angiogenesis-related disorders |
| 01/13/2005 | US20050009140 Elongase genes and uses thereof |
| 01/13/2005 | US20050009073 Polyamide nucleic acid derivatives, and agents, and processes for preparing them |
| 01/13/2005 | US20050009021 Isolated nucleic acid comprising polynucleotide of given sequence; diagnostic kits; use in treatment of cancer |
| 01/13/2005 | US20050008711 Using plant extracts |
| 01/13/2005 | US20050008655 Useful as barrier applied to skin; chemical and radiation resistance; skin disorders; autoimmune diseases; antitumor agents; topical applying |
| 01/13/2005 | US20050008637 Cancer therapy; antiinflammatory agents; autoimmune disease |
| 01/13/2005 | US20050008623 In vitro production of dendritic cells from CD14+ monocytes |
| 01/13/2005 | US20050008614 Herpes virus; papillomas virus; skin; urogenital systems; topical applying; spray dressing |
| 01/13/2005 | CA2572578A1 Herbal composition |
| 01/13/2005 | CA2532066A1 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
| 01/13/2005 | CA2530866A1 Methods and compositions for treating disorders of the extracellular matrix |
| 01/13/2005 | CA2530480A1 Conjugated complement cascade inhibitors |
| 01/13/2005 | CA2530157A1 Barrier formulation comprising a silicone based emulsion |
| 01/12/2005 | EP1495766A1 Factor VII activating protease (FSAP) derived polypeptides for the treatment of angiogenesis-related disorders |
| 01/12/2005 | EP1495764A1 Drinking tea for treating dermatitis |
| 01/12/2005 | EP1495763A1 Therapeutic cream for dermatitis |
| 01/12/2005 | EP1495762A1 Therapeutic lotion for dermatitis |
| 01/12/2005 | EP1495757A1 Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative |
| 01/12/2005 | EP1495756A1 Severe sepsis preventive therapeutic agent |
| 01/12/2005 | EP1495113A2 Stimulation of nerve cell regeneration |
| 01/12/2005 | EP1495111A2 Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells |
| 01/12/2005 | EP1495075A2 Solid emulsions based on thermoplastic elastomers |
| 01/12/2005 | EP1495053A2 Angiopoietin-2 specific binding agents |
| 01/12/2005 | EP1495051A1 Modification of the properties of a fibrin matrix with respect to growth and ingrowth of cells |
| 01/12/2005 | EP1495022A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity |
| 01/12/2005 | EP1495021A2 Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them |
| 01/12/2005 | EP1495020A1 N-(morpholin-2yl) methyl acetamide derivatives as ccr-3 antagonists useful in the treatment of inflammatory diseases |
| 01/12/2005 | EP1495017A2 Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators |
| 01/12/2005 | EP1495016A2 Heterocyclic compounds and their use as modulators of p38 map kinase |
| 01/12/2005 | EP1495005A1 Pyrazole compounds as anti-inflammatory and analgesic agents |
| 01/12/2005 | EP1494993A2 Novel curcumin analogues and uses thereof |
| 01/12/2005 | EP1494992A2 Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 01/12/2005 | EP1494756A2 Chemiluminescent treatment of acne |
| 01/12/2005 | EP1494713A2 Methods for treating tweak-related conditions |
| 01/12/2005 | EP1494701A2 Immunosuppressant compounds, methods and uses related thereto |
| 01/12/2005 | EP1494698A2 Compositions and methods for treating and preventing necrosis |
| 01/12/2005 | EP1494692A1 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis |
| 01/12/2005 | EP1494687A2 Immunomodulatory polymeric antigens for treating inflammatory pathogies |
| 01/12/2005 | EP1494672A1 Aminocarbonyl substituted pyridines, pyridazines, pyrimidines, pyrazines and triazines having antiangiogenic activity |
| 01/12/2005 | EP1494649A1 Nanoparticulate megestrol formulations |
| 01/12/2005 | EP1494638A1 Compositions and methods for inducing new hair follicle formation and hair growth in a desired orientation |
| 01/12/2005 | EP1494634A1 Controlled delivery patch of active ingredient |
| 01/12/2005 | EP1443970A4 Promoters exhibiting endothelial cell specificity and methods of using same |
| 01/12/2005 | EP1365781A4 Acrochordon alleviation |
| 01/12/2005 | EP1307216A4 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 01/12/2005 | EP1299373B1 Cyclic substituted aminomethyl compounds and medicaments containing said compounds |
| 01/12/2005 | EP1185241B1 Compositions containing avenanthramides from oat extract |
| 01/12/2005 | EP1183254B1 Substituted bicyclic heteroaryl compounds as integrin antagonists |
| 01/12/2005 | EP1077711B1 Treatment of papilloma virus infection using a mycobacterium |
| 01/12/2005 | EP1063987A4 Dietary control of arachidonic acid metabolism |
| 01/12/2005 | EP1030851B1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 01/12/2005 | EP1005333B1 Methods and compositions for preventing and treating chronological aging in human skin |
| 01/12/2005 | EP0991628B1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES |
| 01/12/2005 | EP0958823B1 Azelastine hydrochloride-containing percutaneous preparation having good percutaneous absorbability and reduced skin irritation |
| 01/12/2005 | CN1564816A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 01/12/2005 | CN1564811A Acylsulfonamides as inhibitors of steroid sulfatase |
| 01/12/2005 | CN1564689A Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| 01/12/2005 | CN1564685A Pyrrolidinone derivatives |
| 01/12/2005 | CN1564682A Compositions for potentiating glutatthione |
| 01/12/2005 | CN1564681A Treatment of nail infections using NO generating compositions |
| 01/12/2005 | CN1564678A Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 01/12/2005 | CN1564676A Invert emulsion containing DHEA |
| 01/12/2005 | CN1564674A Hair repairing liquid comprising water dispersed with ultrafine particle titanium group metal by plasma underwater discharge and method and system for producing the same |
| 01/12/2005 | CN1562374A fExternal substrate material for attendance of health care |